Table 2.
Characteristics of included studies.
| Study | Sample size | Design | Country | Overall age mean ± SD | Male n (%) | Hypertension n (%) | Cardiovascular disease n (%) | Metformin use n (%) | Insulin use | GLP-1RA use n (%) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death | Alive | ||||||||||
| Cariou B et al.[21] 2020 | 1317 | Retrospective cohort | France | 69.8 ± 13 | 855 (64.9%) | 1003 (77.2%) | 621 (47.1%) | 746 (56.6%) | 504 (38.3%) | 9 (6.4%) | 114 (9.7%) |
| Israelsen SB et al.[22] 2021 | 996 | Retrospective cohort | Denmark | 60 ± 14 | 521 (52.3%) | N/A | N/A | 645 (64.7%) | 224 (24.8%) | 14 (26.4%) | 356 (42%) |
| Izzi-Engbeaya C et al.[23] 2021 | 337 | Retrospective cohort | England | 65.8 ± 17.5 | 202 (60%) | 238 (70.6%) | 91 (27%) | 169 (50.1%) | 108 (31%) | No data on death/alive Total = 5 (1.4%) | |
| Nyland JE et al.[24] 2020 | 12,954 | Retrospective cohort | USA | 62.2 ± 15.2 | 6244 (48.2%) | 5881 (45.4%) | 3420 (26.4%) | 6192 (47.8%) | 7435 (57.4%) | 32 (2.9%) | 797 (6.7%) |
| Orioli L et al.[25] 2021 | 73 | Retrospective cohort | Belgium | 69 ± 14 | 35 (48%) | 59 (80.8%) | 32 (43.8%) | 45 (61.6%) | 31 (45.6%) | 0 (0%) | 5 (8.8%) |
| Ramos-Rincon JM et al.[26] 2021 | 790 | Retrospective cohort | Spain | 85.8 ± 4.5 | 418 (52.9%) | 666 (84.3%) | 625 (79.1%) | 420 (53.1%) | 211 (26.7%) | 11 (2.9%) | 13 (3.3%) |
| Silverii GA et al.[27] 2021 | 159 | Retrospective cohort | Italy | 73.3 ± 12.6 | 86 (54.1%) | N/A | N/A | 76 (47.8%) | 43 (27%) | 1 (1.7%) | 6 (6%) |
| Sourij H et al.[28] 2020 | 238 | Retrospective cohort | Austria | 71.1 ± 12.9 | 152 (63.9%) | 169 (71%) | 160 (67.2%) | 77 (32.3%) | 52 (21.9%) | 0 (0%) | 3 (1.7%) |
| Wargny M et al.[29] 2021 | 2796 | Retrospective cohort | France | 69.7 ± 13.2 | 1782 (63.7%) | 2126 (76.8%) | 302 (11.4%) | 1553 (55.6%) | 1039 (37.2%) | 33 (5.7%) | 221 (10%) |